CmaxInsight Market Intelligence: Market Research Reports

... clients within 1-2 Business Days. CmaxInsight’s, “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor R&D Please note: Certain sections in the ...

... within 1-2 Business Days. CmaxInsight’s, “Leukotriene Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ... client to understand the landscape of the Leukotriene Antagonist. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “Leukotriene D4 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Leukotriene D4 Antagonist. Pipeline Covered: This section mentions all the promising ...

... coverage of MoA enables the client to understand the landscape of the Lipoxygenase Inhibitor (LOX Inhibitor). Pipeline Covered: This section mentions all the promising therapies in different ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor -Pipeline Intelligence, 2019”, report provides ... identifying potential partners with progressing projects for Low Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitor to enhance and expand ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Lysine Specific Demethylase 1 (LSD-1) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Lysine Specific Demethylase 1 (LSD-1) Inhibitor to enhance and expand business ...

... coverage of MoA enables the client to understand the landscape of the Matrix Metalloproteinase (MMP) Inhibitor. Pipeline Covered: This section mentions all the promising therapies in different ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Matrix Metalloproteinase 12 (MMP-12 or Macrophage Metalloelastase) Inhibitor-Pipeline Intelligence, 2019 ... identifying potential partners with progressing projects for Matrix Metalloproteinase 12 (MMP-12 or Macrophage Metalloelastase) Inhibitor to ...

... clients within 1-2 Business Days. CmaxInsight’s, “Matrix Metalloproteinase 9 (MMP-9) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... companies Assess challenges and opportunities that influence Matrix Metalloproteinase 9 (MMP-9) Inhibitor R&D Please note: Certain sections in the ...

... clients within 1-2 Business Days. CmaxInsight’s, “Melanocortin 4 Receptor (MC4R) Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Melanocortin 4 Receptor (MC4R) Agonist R&D Please note: Certain sections in the ...

... coverage of MoA enables the client to understand the landscape of the Metabotropic Glutamate Receptor Agonist. Pipeline Covered: This section mentions all the promising therapies in different ...

... within 1-2 Business Days. CmaxInsight’s, “Methionine Aminopeptidase 2 (Metap2) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Methionine Aminopeptidase 2 (Metap2) Inhibitor R&D Please note: Certain sections in the ...

... 1-2 Business Days. CmaxInsight’s, “mGlu 2/3 Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ... the client to understand the landscape of the mGlu 2/3 Agonist. Pipeline Covered: This section mentions all the promising therapies ...

... 1-2 Business Days. CmaxInsight’s, “mGlu 2/3/5 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the mGlu 2/3/5 Antagonist. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “mGlu5 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the mGlu5 Antagonist. Pipeline Covered: This section mentions all the promising ...

... coverage of MoA enables the client to understand the landscape of the Mitochondrial Electron Transport Inhibitor. Pipeline Covered: This section mentions all the promising therapies in different ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor-Pipeline Intelligence, 2019”, report ... by identifying potential partners with progressing projects for Mitogen Activated Protein Kinase Kinase (MEK or MAP2K) Inhibitor to enhance and ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitor-Pipeline Intelligence, 2019”, ... by identifying potential partners with progressing projects for Mitogen Activated Protein Kinase Kinase 2 (MEK-2 or MAP2K2) Inhibitor to ...

... Days. CmaxInsight’s, “Monoamine Oxidase Inhibitor (MAOIs)-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Monoamine Oxidase Inhibitor (MAOIs). Pipeline Covered: This section mentions all the promising ...

... clients within 1-2 Business Days. CmaxInsight’s, “Monoamine Oxidase B (MAO-B) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Monoamine Oxidase B (MAO-B) Inhibitor R&D Please note: Certain sections in the ...

... within 1-2 Business Days. CmaxInsight’s, “mTORC-1 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the mTORC-1 Inhibitor. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “mTORC-2 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the mTORC-2 Inhibitor. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “Mu Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the Mu Antagonist. Pipeline Covered: This section mentions all the promising therapies ...

... the clients within 1-2 Business Days. CmaxInsight’s, “Murine Double Minute 2 (MDM2) Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights ... identifying potential partners with progressing projects for Murine Double Minute 2 (MDM2) Inhibitor to enhance and expand business potential ...

... within 1-2 Business Days. CmaxInsight’s, “Muscarinic Acetylcholine Receptor (mAChR) Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Muscarinic Acetylcholine Receptor (mAChR) Antagonist R&D Please note: Certain sections in ...

... within 1-2 Business Days. CmaxInsight’s, “Muscarinic Acetylcholine Receptor M2 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Muscarinic Acetylcholine Receptor M2 Antagonist R&D Please note: Certain sections in the ...

... within 1-2 Business Days. CmaxInsight’s, “Muscarinic Acetylcholine Receptor M3 Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Muscarinic Acetylcholine Receptor M3 Antagonist R&D Please note: Certain sections in the ...

... within 1-2 Business Days. CmaxInsight’s, “Muscarinic Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the Muscarinic Agonist. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “Muscarinic M1 Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Muscarinic M1 Agonist. Pipeline Covered: This section mentions all the promising therapies ...

... within 1-2 Business Days. CmaxInsight’s, “Myostatin Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action ( ... the client to understand the landscape of the Myostatin Inhibitor. Pipeline Covered: This section mentions all the promising ...

... Days. CmaxInsight’s, “Neurokinin (NK) Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Neurokinin (NK) Receptor Antagonist. Pipeline Covered: This section mentions all the promising ...

... clients within 1-2 Business Days. CmaxInsight’s, “Neurokinin 1 (NK1) Receptor Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence Neurokinin 1 (NK1) Receptor Agonist R&D Please note: Certain sections in the ...

... to the clients within 1-2 Business Days. CmaxInsight’s, “Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor-Pipeline Intelligence, 2019”, report ... by identifying potential partners with progressing projects for Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor to enhance and ...

... Business Days. CmaxInsight’s, “Neutrophil Elastase Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Neutrophil Elastase Inhibitor. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “NMDA Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the NMDA Receptor Antagonist. Pipeline Covered: This section mentions all the promising ...

... Business Days. CmaxInsight’s, “Non Selective COX Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Non Selective COX Inhibitor. Pipeline Covered: This section mentions all the promising ...

... coverage of MoA enables the client to understand the landscape of the Non-Receptor Tyrosine Kinase Inhibitor. Pipeline Covered: This section mentions all the promising therapies in different ...

... Days. CmaxInsight’s, “Non-Structural Protein 5 Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Non-Structural Protein 5 Inhibitor. Pipeline Covered: This section mentions all the promising ...

... clients within 1-2 Business Days. CmaxInsight’s, “Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitor-Pipeline Intelligence, 2019”, report ... potential partners with progressing projects for Noradrenaline Transporter (NAT or Norepinephrine Transporter or NET) Inhibitor to enhance and ...

... Days. CmaxInsight’s, “Notch Signaling Pathway Inhibitor-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... the client to understand the landscape of the Notch Signaling Pathway Inhibitor. Pipeline Covered: This section mentions all the promising ...

... 1-2 Business Days. CmaxInsight’s, “Nrf2 Pathway Activators-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Nrf2 Pathway Activators. Pipeline Covered: This section mentions all the promising ...

... clients within 1-2 Business Days. CmaxInsight’s, “Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI)s-Pipeline Intelligence, 2019”, report provides comprehensive ... identifying potential partners with progressing projects for Nucleotide Analog Reverse Transcriptase Inhibitor (NtRTI)s to enhance and expand ...

... 1-2 Business Days. CmaxInsight’s, “Opioid Receptor Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the Opioid Receptor Agonist. Pipeline Covered: This section mentions all the promising ...

... within 1-2 Business Days. CmaxInsight’s, “Orexin Receptor (Hypocretin Receptor) Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive ... companies Assess challenges and opportunities that influence Orexin Receptor (Hypocretin Receptor) Antagonist R&D Please note: Certain sections in the ...

... coverage of MoA enables the client to understand the landscape of the Ornithine Decarboxylase (ODC) Inhibitor. Pipeline Covered: This section mentions all the promising therapies in different ...

... within 1-2 Business Days. CmaxInsight’s, “OX-40 Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of action (MoA ... the client to understand the landscape of the OX-40 Agonist. Pipeline Covered: This section mentions all the promising therapies ...

... 1-2 Business Days. CmaxInsight’s, “P2X7 Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism of ... the client to understand the landscape of the P2X7 Receptor Antagonist. Pipeline Covered: This section mentions all the promising ...

... clients within 1-2 Business Days. CmaxInsight’s, “P2Y12 Platelet ADP Receptor Antagonist-Pipeline Intelligence, 2019”, report provides comprehensive insights ... leading companies Assess challenges and opportunities that influence P2Y12 Platelet ADP Receptor Antagonist R&D Please note: Certain sections in the ...

... clients within 1-2 Business Days. CmaxInsight’s, “p70S6 Kinase (p70S6K or 70-kDa Ribosomal Protein S6 Kinase) Inhibitor-Pipeline Intelligence, 2019”, report provides ... potential partners with progressing projects for p70S6 Kinase (p70S6K or 70-kDa Ribosomal Protein S6 Kinase) Inhibitor to enhance and expand ...

... Days. CmaxInsight’s, “Parathyroid Hormone Receptor Agonist-Pipeline Intelligence, 2019”, report provides comprehensive insights about pipeline drugs across this mechanism ... client to understand the landscape of the Parathyroid Hormone Receptor Agonist. Pipeline Covered: This section mentions all the promising ...